When was Esperion Therapeutics founded?

Esperion Therapeutics was founded in 1998 and raised its 1st funding round 1 year after it was founded.

Where is Esperion Therapeutics located?

Esperion Therapeutics is headquartered in Ann Arbor, United States. It is registered at 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108.

Who is the current CEO of Esperion Therapeutics?

Timothy Mayleben of Esperion Therapeutics.

How many employees does Esperion Therapeutics have?

As of Sep 30, 2026, the latest employee count at Esperion Therapeutics is 354.

Is Esperion Therapeutics a funded company?

Esperion Therapeutics is a funded company, having raised a total of $107M across 8 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 08, 1999.

How much is Esperion Therapeutics worth?

The last known valuation of Esperion Therapeutics was $***** as of Oct 18, 2017.

When was the latest funding round of Esperion Therapeutics?

Esperion Therapeutics' latest funding was a $***** Post IPO round on Apr 26, 2021, with participation from 1 investor.

Where does Esperion Therapeutics rank among its competitors?

Esperion Therapeutics ranks 6th amongst 368 active competitors, of which 111 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejuvenate Bio, which secured $19.5M in Jun, 2026.

Who are the top competitors of Esperion Therapeutics?

Esperion Therapeutics' top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Rejuvenate Bio secured the most recent funding round in June, 2026.

Esperion Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Esperion Therapeutics is an acquired company based in Ann Arbor (United States), founded in 1998. It operates as a Developer of lipoprotein cholesterol (LDL-C) lowering therapies. Esperion Therapeutics has raised $107M in funding from investors like Alta Partners, Canaan and Domain Associates, with last known valuation of $*****. The company has 368 active competitors, including 111 funded and 105 that have exited. Its top competitors include companies like argenx, Tenaya Therapeutics and Vor Biopharma.

Company Details

Developer of lipoprotein cholesterol (LDL-C) lowering therapies. Its drug pipeline includes Bempedoic Acid (ETC-1002) (Inhibitor of ATP Citrate Lyase) which is low-density lipoprotein cholesterol (LDL-C) lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies; ESP41091 and ApoA-1 Mimetics.

Website: esperion.com
Social
Registered Address: 3891 Ranchero Drive Suite 150 Ann Arbor, MI 48108

Key Metrics

Founded Year

1998

Location

Ann Arbor, United States

Stage

Acquired

Total Funding

$107M in 8 rounds

Latest Funding Round

Post IPO, Apr 26, 2021, $*****

Last Known Valuation

$***** as on Oct 18, 2017

Investors

Alta Partners & 17 more

Ranked

6^th among 368 active competitors

Employee Count

354 as on Sep 30, 2026

Investment & Acquisitions

Corstasis Therapeutics

Similar Companies

Tenaya Therapeutics & 347 more

Exit Details

Acquired by ARCHIMED (May 01, 2026)

View Esperion Therapeutics' full profile

Esperion Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Esperion Therapeutics, Inc. CIN: 1434868 , United States, Active		$100M - $500M (As on Dec 31, 2025)	240 (As on Dec 31, 2023)	-
ESPERION THERAPEUTICS, INC. CIN: 26-1870780 , United States, Active	May 17, 1998	-	218 (As on Dec 31, 2021)	-
ESPERION THERAPEUTICS CIN: 261870780 , United States, Active	Dec 31, 1999	-	307 (As on Dec 31, 2024)	-

Esperion Therapeutics got acquired by ARCHIMED on May 01, 2026.

Click here to take a look at Esperion Therapeutics's acquisition in detail

Esperion Therapeutics has raised a total funding of $107M over 8 rounds. Its first funding round was on Nov 08, 1999. Its latest funding round was a Post IPO round on Apr 26, 2021 for $*****. 1 investor participated in its latest round. Esperion Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Esperion Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 26, 2021	9993374	Post IPO	4865155	1410438	7690890	3077452
Nov 12, 2020	6990610	Post IPO	7384579	7216724	2852388	1132982
Apr 24, 2013	2789133	Series B	4786842	3119957	Longitude Capital	Aisling Capital & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Esperion Therapeutics's funding rounds and investors

Esperion Therapeutics' employee count trend

Esperion Therapeutics has 354 employees as of Sep 26. Here is Esperion Therapeutics's employee count trend over the years:

Employee count trend for Esperion Therapeutics

Uncover Esperion Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Esperion Therapeutics include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Esperion Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Fidelity Investments, Sofinnova Investments ... & 8 others	66/100
5th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
6th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	BB Biotech, Oberland Capital & 16 others	63/100
7th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Deep Track Capital & 17 others	65/100
8th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
9th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
10th	Rejuvenate Bio 2018, San Diego (United States), Series A	Developer of gene therapies for treating chronic and age-related diseases	$34M	VCapital, Digitalis Ventures & 12 others	62/100